Next-generation sequencing

While monoclonal antibodies against EGFR, such as cetuximab and panitumumab, can block the growth and spread of colorectal cancer, studies have shown that tumors with specific gene mutations will not respond to these therapies. Based on internal Mayo Clinic data, Mayo Clinic Laboratories’ expanded genetic panel identified 24% more patients who are unlikely to benefit from EGFR-targeted therapy. Our next-generation sequencing panel was designed to meet current guidelines and remain targeted enough to provide clinically actionable results.

Key testing

• MCCRC | MayoComplete Colorectal Cancer Panel, Next-Generation Sequencing, Tumor

Advantages

• Enables insights on diagnosis, prognosis, and treatment response by sequencing APC, BRAF, HRAS, KRAS, MLH1, MSH2, MSH6, NRAS, and PMS2.
• Provides MSI status.

• KRASD | Cell-Free DNA KRAS 12, 13, 61,146, Blood

Advantages

• Offers cell-free DNA testing on peripheral blood when tumor testing is not available for CRC patients.
• Detects the presence of common KRAS mutations at codons 12, 13, 61, and 146.

---

Anti-PD-L1 immunotherapy

Anti-PD-L1 immunotherapies such as pembrolizumab have recently emerged as a therapeutic option in CRC. These therapies are designed to block the PD-L1/PD-1 immune checkpoint pathway, thereby assisting the immune system in tumor cell detection. However, current data indicates that only patients with defective MMR and/or high MSI are likely to benefit from this therapy. Our rapid tumor microsatellite instability (TMSI) evaluation is the only clinically available assay of its kind to offer fast test results.

Key testing

• TMSI | Microsatellite Instability, Tumor
• IHC | Mismatch Repair (MMR) Protein Immunohistochemistry Only, Tumor